MSC-Exosomes as Novel Therapeutics in Asthma and Allergic Airway Inflammation

INTRODUCTION: Through these mechanisms, MSC-Exos effectively attenuate airway hyperreactivity and remodeling, leading to functional improvement in preclinical asthma models. MSC-Exos exert their therapeutic effects through multiple mechanisms, including modulation of immune cell activity, suppression of Th2 cytokines, and promotion of Treg and M2 macrophage responses that collectively alleviate airway inflammation (Figure 1). CONCLUSION: Collectively, these findings indicate that MSC-Exos can recapitulate many of the beneficial immunomodulatory effects of MSC therapy while avoiding several of the risks associated with live cell transplantation, such as immune rejection or tumorigenicity. A major advantage of MSC-Exos therapy is its cell-free and safer nature, avoiding risks associated with stem cell transplantation. Due to their nanoscale size, lipid bilayer structure, and endogenous cargo, MSC-Exos can efficiently deliver regulatory molecules to target tissues, outperforming many synthetic nanocarrier systems. Nevertheless, translating these promising preclinical findings into clinical practice requires overcoming several challenges, including standardized isolation and characterization protocols, scalable GMP-compliant production, dose optimization, and rigorous long-term safety evaluation. Future Perspectives: MSC-Exos represent an innovative and safe therapeutic platform for allergic respiratory diseases such as asthma and rhinitis. By combining the regenerative and immunomodulatory properties of MSCs with the advantages of a cell-free system, they effectively regulate Th2 cytokines and restore immune balance. Future research should prioritize the scalable production and bioengineering optimization of MSC-Exos to enhance their stability, targeting efficiency, and bioactivity. Advances in exosome surface modification, such as ligand conjugation or genetic engineering of parent MSCs, may further improve selective delivery to inflamed airway tissues. Additionally, large-scale clinical trials are necessary to confirm therapeutic efficacy, establish optimal administration routes (e.g., intranasal vs. systemic), and ensure long-term safety. Beyond allergic airway diseases, the versatility of MSC-Exos may extend to other inflammatory and fibrotic lung conditions, including chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. As understanding of exosome biology deepens and bioengineering techniques advance, MSC-Exos are poised to become a cornerstone of next-generation immunomodulatory and regenerative therapies, bridging molecular biology, nanotechnology, and clinical immunology for transformative outcomes in respiratory medicine.